Your session is about to expire
← Back to Search
Senolytic
Senolytics for Alzheimer's Disease
Phase 1 & 2
Waitlist Available
Led By Ronald C Petersen, MD, PhD
Research Sponsored by James L. Kirkland, MD, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 11 weeks
Awards & highlights
Study Summary
This trial is testing if a combination of Dasatinib and Quercetin is safe and effective in treating Mild Cognitive Impairment or Alzheimer's disease.
Who is the study for?
This trial is for men and women aged 55 or older with Mild Cognitive Impairment or Alzheimer's, confirmed by brain imaging showing Tau protein. They must not be on certain dementia medications or if they are, the dose should be stable for three months. Participants need a legal representative to consent and attend visits, have no major travel plans for about three months, and meet specific health criteria like adequate blood counts.Check my eligibility
What is being tested?
The ALSENLITE study tests the combination of two drugs, Dasatinib and Quercetin, to see if they're safe and can work in people with Mild Cognitive Impairment (MCI) or Alzheimer's disease. The goal is to understand how these drugs affect cognitive impairment associated with Alzheimer's.See study design
What are the potential side effects?
Potential side effects from Dasatinib may include fluid retention, bleeding problems, fatigue, digestive issues; while Quercetin could cause headaches and tingling sensations. Side effects vary between individuals.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 11 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~11 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety and Tolerability of 11 week of intermittent D+Q treatment
Side effects data
From 2022 Phase 2 trial • 54 Patients • NCT0302304626%
Febrile neutropenia
17%
Sepsis
9%
Mucositis oral
4%
Upper gastrointestinal hemorrhage
4%
Intracranial hemorrhage
4%
Hypotension
4%
Hypertension
4%
Enterocolitis
2%
Atrial fibrillation
2%
Lower gastrointestinal hemorrhage
2%
Delirium
2%
Oropharyngeal pain
2%
Gastric hemorrhage
2%
Abdominal pain
2%
Diarrhea
2%
Fungemia
2%
Typhlitis
2%
Myocardial infarction
2%
Fibrinogen decreased
2%
Endophthalmitis
2%
Multi-organ failure
2%
Kidney infection
2%
Peripheral motor neuropathy
2%
Hypoxia
2%
Sinus bradycardia
2%
Edema limbs
2%
Small intestinal obstruction
2%
Aspiration
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment (Chemotherapy)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Dasatinib plus Quercetin Treatment GoupExperimental Treatment2 Interventions
Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Quercetin
2010
Completed Phase 4
~700
Dasatinib
2012
Completed Phase 3
~2320
Find a Location
Who is running the clinical trial?
James L. Kirkland, MD, PhDLead Sponsor
1 Previous Clinical Trials
55 Total Patients Enrolled
Ronald C Petersen, MD, PhDPrincipal InvestigatorMayo Clinic
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your lab test results are not normal, or a doctor thinks there may be a problem based on your overall health.Your heart's electrical activity (measured by an ECG) shows a QTc interval longer than 450 milliseconds.You have a mental health condition that is not currently under control.You have uncontrolled systemic lupus erythematosus, as determined by a doctor.You regularly drink more than 3 alcoholic drinks per day or more than 21 drinks per week.You have a condition that makes it difficult for your body to absorb nutrients from food.Your kidney function is very low, less than 10 ml/min/1.73 m2.You have been diagnosed with symptomatic probable Alzheimer's disease and have a certain range of scores on memory and mental tests.You are not taking certain medications for memory and thinking problems, or if you are, you have been on a steady dose for at least three months.You have been diagnosed with HIV.You have a current hepatitis B or C infection.You have a serious fungal or viral infection, as determined by a doctor.You are allergic to D or Q.Your diabetes is not well controlled, which means your HbA1c level is higher than 7%.You have had a surgery to reduce the size of your stomach.You have Crohn's disease.You have certain muscle conditions or abnormal levels of calcium, vitamin D, or certain blood tests.Your kidneys are not working well enough, as measured by a test called creatinine clearance.You are taking certain medications to prevent blood clots.You are taking strong blood thinners like Aspirin or Clopidogrel, but may be allowed to take a low dose aspirin if it's necessary for your heart health.Your body mass index (BMI) is between 19 and 50.You have long-term heart problems according to your doctor's assessment.You have a medical condition that makes it hard for you to do the physical tests required for the study.You have severe liver disease with high levels of bilirubin.You have excessive fluid buildup around your lungs, heart, or abdomen that is not being controlled.You have any type of cancer that is growing or has been diagnosed recently, except for non-melanoma skin cancers.You cannot handle taking pills, according to the doctor's decision.You are currently taking certain medications that cannot be stopped safely during the study treatment and for 36 hours after the treatment.People who are 55 years old or older when they join the study.You have evidence of tau buildup in your brain shown by a PET scan.Your blood counts must show enough platelets, hemoglobin, and white blood cells.Even with glasses or hearing aids, you have trouble hearing, seeing, or moving.You have had a heart attack, chest pain, stroke, or temporary stroke-like symptoms in the past 6 months.You have tested positive for COVID-19 in the last 30 days before joining the study.Your liver enzymes (AST/ALT) are more than 2.5 times the normal limit.
Research Study Groups:
This trial has the following groups:- Group 1: Dasatinib plus Quercetin Treatment Goup
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many individuals have been admitted to this trial?
"This study is no longer enrolling patients as the posted date was July 6th 2022 and has not been updated since September 9th 2022. If you are interested in joining other trials, there are currently 980 studies related to Alzheimer's disease and 68 Dasatinib-related studies actively recruiting participants."
Answered by AI
Are any fresh participants currently being recruited for this trial?
"The information hosted on clinicaltrials.gov suggests that this medical study is not presently enrolling; although it was initially posted in July and updated last month, there are no active openings for participants at the moment. Nonetheless, 1048 other trials have open admissions right now."
Answered by AI
Are there any other trials that have explored the efficacy of Dasatinib?
"At present, 68 clinical trials are underway researching Dasatinib. Of those 69 studies, 9 are operating in their third phase. Most of the research is hosted at locations within New york City but there exist 4262 sites globally trialing this medication."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger